Key Takeaways from Recent EASD Guidelines
The most critical takeaway from recent EASD consensus is that GLP-1 receptor agonists and SGLT2 inhibitors should be initiated based on cardiovascular and renal risk profiles independent of HbA1c levels, with early combination therapy strongly favored over stepwise approaches to avoid therapeutic inertia. 1
Paradigm Shift: Risk-Based Rather Than Glucose-Based Treatment
The fundamental change in diabetes management is moving away from glucose-centric care to organ protection:
For patients with established atherosclerotic CVD (prior MI, stroke, revascularization): GLP-1 receptor agonists have the strongest evidence for MACE reduction, showing 12% reduction in 3-point MACE, 11% reduction in all-cause mortality, and 16% reduction in fatal/non-fatal stroke 2
**For patients with heart failure (EF <45%) or CKD** (eGFR 30-60 mL/min or albuminuria >30 mg/g): SGLT2 inhibitors are the clear choice, demonstrating superiority in reducing hospitalization for heart failure, preventing CKD progression, and reducing cardiovascular death 2, 1
Early Combination Therapy is Now Standard
Avoid therapeutic inertia by initiating combination therapy upfront, particularly in:
- Patients with HbA1c >70 mmol/mol (>8.5%) at diagnosis
- Younger patients with type 2 diabetes regardless of HbA1c
- Any patient where stepwise approach would delay access to cardio-renal protective agents 1
The evidence is clear: incorporate rather than substitute therapies with complementary mechanisms of action. Fixed-dose combinations should be considered to reduce prescription burden 1.
Insulin's Diminished Role
GLP-1 receptor agonists should be considered before insulin initiation in all patients without contraindications 1. This represents a major shift from historical practice. Insulin remains indicated only for:
- Severe hyperglycemia (HbA1c >86 mmol/mol or >10%) with weight loss/ketosis
- Acute illness, hospitalization, or surgery
- Suspected type 1 diabetes
- Underweight patients
When insulin is necessary, basal insulin analogues are preferred over NPH due to reduced hypoglycemia risk 1.
Risk Stratification Drives Treatment Selection
The ESC/EASD framework classifies patients into three cardiovascular risk levels, with treatment decisions made independent of baseline HbA1c 2:
High-risk indicators for GLP-1 RA consideration (even without established CVD):
- Age ≥55 years with >50% stenosis in coronary, carotid, or lower extremity arteries
- Left ventricular hypertrophy
- eGFR <60 mL/min/1.73m²
- Albuminuria (particularly >300 mg/g) 2
Critical Pitfalls to Avoid
Therapeutic inertia remains the primary enemy: The SOLVE study confirms that despite effective therapies and clear guidelines, clinicians delay treatment intensification 3. Re-evaluate at every visit and avoid waiting for HbA1c to worsen before adding cardio-renal protective agents 1.
Foot care with SGLT2 inhibitors: Patients with foot ulcers or high amputation risk require careful shared decision-making and comprehensive foot care education before SGLT2 inhibitor initiation 2.
De-intensification matters: In frail older adults or those with hypoglycemia risk on medications substantially exceeding glycemic targets, consider reducing therapy burden 1.
The Meta-Analysis Evidence Base
GLP-1 receptor agonists (pooled data from 56,004 participants) demonstrate:
- 12% reduction in cardiovascular death
- 17% reduction in broad kidney composite outcomes (mainly albuminuria-driven)
- 9% reduction in heart failure hospitalization 2
This evidence comes from trials where the majority of patients were already on metformin, confirming metformin remains foundational therapy while these agents provide additional organ protection 4.